|Application ||WB, IHC-P, IF, FC, E|
|Calculated MW||101128 Da|
|Antigen Region||299-330 aa|
|Other Names||Epithelial discoidin domain-containing receptor 1, Epithelial discoidin domain receptor 1, CD167 antigen-like family member A, Cell adhesion kinase, Discoidin receptor tyrosine kinase, HGK2, Mammary carcinoma kinase 10, MCK-10, Protein-tyrosine kinase 3A, Protein-tyrosine kinase RTK-6, TRK E, Tyrosine kinase DDR, Tyrosine-protein kinase CAK, CD167a, DDR1, CAK, EDDR1, NEP, NTRK4, PTK3A, RTK6, TRKE|
|Target/Specificity||This DDR1 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 299-330 amino acids from the Central region of human DDR1.|
|Format||Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS.|
|Precautions||DDR1 Antibody (Center) is for research use only and not for use in diagnostic or therapeutic procedures.|
|Synonyms||CAK, EDDR1, NEP, NTRK4, PTK3A, RTK6, TRK|
|Function||Tyrosine kinase that functions as cell surface receptor for fibrillar collagen and regulates cell attachment to the extracellular matrix, remodeling of the extracellular matrix, cell migration, differentiation, survival and cell proliferation. Collagen binding triggers a signaling pathway that involves SRC and leads to the activation of MAP kinases. Regulates remodeling of the extracellular matrix by up-regulation of the matrix metalloproteinases MMP2, MMP7 and MMP9, and thereby facilitates cell migration and wound healing. Required for normal blastocyst implantation during pregnancy, for normal mammary gland differentiation and normal lactation. Required for normal ear morphology and normal hearing (By similarity). Promotes smooth muscle cell migration, and thereby contributes to arterial wound healing. Also plays a role in tumor cell invasion. Phosphorylates PTPN11.|
|Cellular Location||Isoform 1: Cell membrane; Single-pass type I membrane protein Isoform 3: Secreted.|
|Tissue Location||Detected in T-47D, MDA-MB-175 and HBL-100 breast carcinoma cells, A-431 epidermoid carcinoma cells, SW48 and SNU-C2B colon carcinoma cells and Hs 294T melanoma cells (at protein level). Expressed at low levels in most adult tissues and is highest in the brain, lung, placenta and kidney. Lower levels of expression are detected in melanocytes, heart, liver, skeletal muscle and pancreas. Abundant in breast carcinoma cell lines. In the colonic mucosa, expressed in epithelia but not in the connective tissue of the lamina propria. In the thyroid gland, expressed in the epithelium of the thyroid follicles. In pancreas, expressed in the islets of Langerhans cells, but not in the surrounding epithelial cells of the exocrine pancreas. In kidney, expressed in the epithelia of the distal tubules. Not expressed in connective tissue, endothelial cells, adipose tissue, muscle cells or cells of hematopoietic origin.|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Receptor tyrosine kinases (RTKs) play a key role in the communication of cells with their microenvironment. These molecules are involved in the regulation of cell growth, differentiation and metabolism. DDR1 is an RTK that is widely expressed in normal and transformed epithelial cells and is activated by various types of collagen. It belongs to a subfamily of tyrosine kinase receptors with a homology region to the Dictyostelium discoideum protein discoidin I in their extracellular domain. Its autophosphorylation is achieved by all collagens so far tested (type I to type VI). In situ studies and Northern-blot analysis show that expression of DDR1 is restricted to epithelial cells, particularly in the kidney, lung, gastrointestinal tract, and brain. In addition, it is significantly over-expressed in several human tumors from breast, ovarian, esophageal, and pediatric brain.
Johnson J.D.,Proc. Natl. Acad. Sci. U.S.A. 90:5677-5681(1993)
Sakuma S.,FEBS Lett. 398:165-169(1996)
If you have any additional inquiries please email technical services at firstname.lastname@example.org.